Medisch Centrum Leeuwarden B.V.
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
At Medisch Centrum Leeuwarden B.V., researchers are advancing diagnostic imaging and therapeutic technologies to improve patient care across multiple disease areas.
- Tau PET imaging for dementia
- Selective decontamination of the digestive tract (SDD) after esophagectomy
- Advanced biomarker assays for treatment monitoring
These initiatives support the hospital’s commitment to integrating cutting‑edge techniques into routine clinical practice.
Bacterial Infections and Mycoses
Clinical studies focus on innovative antimicrobial strategies to combat prosthetic joint infections and other hard‑to‑treat bacterial diseases.
- Prosthetic joint infection treatment comparison
- Targeted oral clindamycin monotherapy
- Evaluation of rifampicin‑based regimens
The trials aim to reduce infection recurrence and enhance recovery for patients undergoing orthopedic procedures.
Cardiovascular Diseases
Investigators are testing novel agents to lower the risk of heart attacks, strokes, and other vascular events, including lipid‑lowering RNA therapeutics and rapid‑action anti‑platelet drugs.
- Inclisiran for major adverse cardiovascular events
- Selatogrel self‑administration in acute myocardial infarction
- Aspirin omission study in non‑ST‑segment elevation acute coronary syndrome
- Primary prevention of ASCVD in high‑risk individuals
These trials, conducted at the Leeuwarden site, seek to improve long‑term cardiovascular outcomes and patient quality of life.
Digestive System Diseases
The center conducts trials on esophageal and gastric cancers, exploring combined chemoradiation, surgical adjuncts, and personalized treatment based on molecular profiling.
- Esophageal squamous cell carcinoma with bintrafusp alfa
- Gastric adenocarcinoma pre‑operative regimen comparison
- Selective decontamination after esophagectomy
- MMRd high‑risk endometrial cancer adjuvant therapy
Research integrates surgical, systemic, and immunologic approaches to boost survival for gastrointestinal malignancies.
Hemic and Lymphatic Diseases
A broad portfolio of trials addresses blood‑cancer subtypes, evaluating targeted therapies, immunotherapies, and combination regimens to increase remission rates.
- Acute myeloid leukemia with venetoclax‑cobicistat
- IDH‑mutated AML/MDS with ivosidenib or enasidenib
- FLT3‑mutated AML with gilteritinib or midostaurin
- Relapsed Hodgkin lymphoma with tislelizumab
- High‑grade B‑cell lymphoma with nivolumab consolidation
The site’s hematology program leverages precision medicine to improve survival for patients with complex hematologic malignancies.
Male Urogenital Diseases
Research includes a strategic trial evaluating the optimal duration of androgen‑receptor signalling inhibition in low‑volume metastatic prostate cancer.
- Shortened 12‑month ARSI therapy versus continuous treatment
- Assessment of disease control and toxicity
- Quality‑of‑life outcomes in prostate cancer patients
Findings could redefine standard care by balancing efficacy with reduced side‑effects for men with prostate cancer.
Musculoskeletal Diseases
Studies target inflammatory spinal disorders and joint infections, aiming to reduce disease activity and improve functional status.
- Filgotinib for axial spondyloarthritis
- Prosthetic joint infection antibiotic strategies
- Evaluation of SDD to prevent postoperative pneumonia
- Patient‑reported outcomes in musculoskeletal trials
These investigations support comprehensive management of both autoimmune and infection‑related musculoskeletal conditions.
Neoplasms
A diverse array of oncology trials investigates novel immunotherapies, antibody‑drug conjugates, and combination regimens across solid tumours and lymphomas.
- DA‑EPOCH‑R followed by nivolumab for high‑grade B‑cell lymphoma
- Epcoritamab plus R‑CHOP in diffuse large B‑cell lymphoma
- Atezolizumab consolidation in high‑risk DLBCL
- Combination therapy for esophageal squamous cell carcinoma
- Targeted therapy for endometrial cancer with MMRd
Medisch Centrum Leeuwarden’s oncology unit strives to bring innovative treatments from bench to bedside for a wide spectrum of cancers.
Nervous System Diseases
Clinical work focuses on early detection of cognitive decline and prevention of recurrent cerebrovascular events through advanced imaging and therapeutic interventions.
- Tau PET imaging for dementia diagnosis
- Statin discontinuation versus continuation after stroke
- Management of mild cognitive impairment
- Assessment of ischemic stroke recurrence risk
The aim is to enhance diagnostic precision and optimize secondary prevention strategies for patients with neurological disorders.
Respiratory Tract Diseases
Trials evaluate biologic therapies and inhaled treatments to reduce exacerbations and improve lung function in chronic obstructive pulmonary disease and small‑cell lung cancer.
- Benralizumab for severe COPD with frequent exacerbations
- Extensive‑stage small‑cell lung cancer combination therapy
- Evaluation of respiratory outcomes in cancer patients
- Biomarker‑guided therapy for lung disease
These studies aim to lessen disease burden and extend survival for individuals affected by serious respiratory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 72 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medisch Centrum Leeuwarden B.V.
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 72 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2022-04-01 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.